- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Aug 14, 2024
Deals
Deals Report: Pair of Merck deals in APAC region; Recursion and Exscientia merging
Plus: Denmark-based Pharmacosmos buys G1, obtaining myelosuppression drug
BioCentury | Jul 22, 2024
Deals
Deals Report: Sionna looks to AbbVie for cystic fibrosis combos as Vertex-Orum strike degrader deal
Week's deals also include a radionuclide conjugate partnership between SK and Full-Life, and GT Apeiron hands off CDK7 to Exscientia
BioCentury | Oct 7, 2023
Politics, Policy & Law
Oct. 6 Quick Takes: CBO says covering anti-obesity medications won’t save money
Plus: Amgen Horizon deal closes and updates from Exscientia, Scleroderma Research Foundation, 7wireVentures and Orakl
BioCentury | Sep 20, 2023
Discovery & Translation
Driving translational science, a conversation with Dennis Liotta
How changing the model for science funding to include investing in development could speed biomedical progress
BioCentury | Dec 3, 2022
Finance
Dec. 2 Quick Takes: Liminatus heads for NASDAQ via SPAC deal
Plus: FDA clears Beam’s CD7-targeting CAR T for clinical trial, and updates from GSK, Theratechnologies, PictorLabs and more
BioCentury | Mar 30, 2022
Product Development
March 29 Quick Takes: Pfizer preps etrasimod submissions after second Phase III readout
Plus Innovent, Lilly expand oncology partnership and updates from InnoRNA, ImmunoGen and more
BioCentury | Feb 5, 2022
Deals
Evotec shares sag as Bayer terminates P2X3 program, returns rights
Bayer hands back P2X3 program to Evotec soon after Merck’s therapy hits regulatory snag
Items per page:
1 - 10 of 42